LOGIN  |  REGISTER
Cue Biopharma
Astria Therapeutics

Bob Glazer Joins Phreesia as Strategic Advisor

August 08, 2024 | Last Trade: US$18.46 0.03 -0.16
  • Phreesia Welcomes Former CEO of ENT and Allergy Associates

ALL-REMOTE COMPANY/WILMINGTON, Del. / Aug 08, 2024 / Business Wire / Phreesia, a leader in patient intake, outreach and activation, is pleased to announce it has named Bob Glazer as a Strategic Advisor, leveraging his deep expertise and decades of experience in healthcare leadership to help ensure its offerings continue to meet the evolving needs of its clients.

Glazer, whose career spans more than 45 years, is currently the President of Glazer Business Advisors, a consulting group that advises physician practices in areas such as physician recruitment, revenue cycle management, mergers and acquisitions, and strategic planning. Glazer spent 27 years as CEO of ENT and Allergy Associates (ENTA), the largest ENT, allergy and audiology practice in the country, and a longtime Phreesia client. During his tenure, ENTA grew from 12 to 250 providers, with more than 50 locations across New York and New Jersey.

“We’re so excited to have Bob as an advisor,” said Phreesia COO Evan Roberts. “We worked very closely with him when he was a client at ENTA, and he really understands the on-the-ground reality for medical practices—especially in the single-specialty space—and how to set them up for success. We believe that his perspective and broad expertise is going to be incredibly valuable for us.”

In addition to his role at Glazer Business Advisors, Glazer also serves as an advisor to a number of physician groups, helping with business development, recruiting, revenue expansion and other areas.

“At this stage of my career, my goal is really to help the next generation of physicians, and I’m confident that joining Phreesia as an advisor is a great way to accomplish that,” said Glazer. “When I was at ENTA, Phreesia was a true partner that was always willing to put in the time and resources to support us. I’m looking forward to helping them do that for other groups that are on the frontier of new challenges, like engaging patients and making sure they get the care they need.”

About Phreesia

Phreesia is the trusted leader in patient activation, giving providers, life sciences companies, payers and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 150 million patient visits in 2023—more than 1 in 10 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB